Viracta Therapeutics Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 38

Employees

  • Stock Symbol
  • VIRX

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.01
  • (As of Monday Closing)

Viracta Therapeutics General Information

Description

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

Contact Information

Website
www.viracta.com
Formerly Known As
Hemagenex Pharmaceuticals, HemaQuest Pharmaceuticals, Sunesis
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2533 South Coast Highway 101
  • Suite 210
  • Cardiff, CA 92007
  • United States
+1 (858)
Primary Industry
Drug Discovery
Stock Exchange
PINX
Vertical(s)
Corporate Office
  • 2533 South Coast Highway 101
  • Suite 210
  • Cardiff, CA 92007
  • United States
+1 (858)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Viracta Therapeutics Stock Performance

As of 14-Jul-2025, Viracta Therapeutics’s stock price is $0.01. Its current market cap is $401K with 39.7M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.01 $0.01 $401K 39.7M 119K -$1.10

Viracta Therapeutics Financials Summary

As of 30-Sep-2024, Viracta Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 3,387 (9,924) (10,600) 36,431
Revenue 0 0 0 0
EBITDA (41,781) (50,207) (49,581) (114,131)
Net Income (43,289) (51,058) (49,197) (114,762)
Total Assets 21,958 56,692 95,991 108,552
Total Debt 16,911 25,556 25,155 5,478
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Viracta Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Viracta Therapeutics‘s full profile, request access.

Request a free trial

Viracta Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Viracta Therapeutics‘s full profile, request access.

Request a free trial

Viracta Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-as
Drug Discovery
Cardiff, CA
38 As of 2025

Cambridge, MA
 

Vancouver, WA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Viracta Therapeutics Competitors (56)

One of Viracta Therapeutics’s 56 competitors is Blueprint Medicines, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Blueprint Medicines Formerly VC-backed Cambridge, MA
Cytodyn Formerly Angel backed Vancouver, WA
NexImmune Formerly VC-backed Gaithersburg, MD
Kite Pharma Formerly VC-backed Santa Monica, CA
Peloton Therapeutics Formerly VC-backed Dallas, TX
You’re viewing 5 of 56 competitors. Get the full list »

Viracta Therapeutics Patents

Viracta Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10953011-B2 Methods of treating virally associated cancers with histone deacetylase inhibitors Active 31-May-2019
US-20200375990-A1 Methods of treating virally associated cancers with histone deacetylase inhibitors Active 31-May-2019
US-20220226322-A1 Methods of treating virally associated cancers with histone deacetylase inhibitors Inactive 31-May-2019
US-20190175589-A1 Pharmaceutical formulations, processes for preparation, and methods of use Inactive 09-Nov-2017
US-20200390764-A1 Pharmaceutical formulations, processes for preparation, and methods of use Inactive 09-Nov-2017 A61K31/4985
To view Viracta Therapeutics’s complete patent history, request access »

Viracta Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Viracta Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Viracta Therapeutics‘s full profile, request access.

Request a free trial

Viracta Therapeutics Investments & Acquisitions (2)

Viracta Therapeutics’s most recent deal was a Merger/Acquisition with Sunesis. The deal was made on 24-Feb-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Sunesis 24-Feb-2021 Merger/Acquisition Biotechnology
Chroma Therapeutics (VRx-3996 Drug Development and Research Rights) 30-Nov-2016 Corporate Asset Purchase Buildings and Property
To view Viracta Therapeutics’s complete investments and acquisitions history, request access »

Viracta Therapeutics ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

32.78 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,912

Rank

Percentile

Pharmaceuticals

Industry

of 965

Rank

Percentile

Biotechnology

Subindustry

of 443

Rank

Percentile

To view Viracta Therapeutics’s complete esg history, request access »

Viracta Therapeutics FAQs

  • When was Viracta Therapeutics founded?

    Viracta Therapeutics was founded in 1998.

  • Where is Viracta Therapeutics headquartered?

    Viracta Therapeutics is headquartered in Cardiff, CA.

  • What is the size of Viracta Therapeutics?

    Viracta Therapeutics has 38 total employees.

  • What industry is Viracta Therapeutics in?

    Viracta Therapeutics’s primary industry is Drug Discovery.

  • Is Viracta Therapeutics a private or public company?

    Viracta Therapeutics is a Public company.

  • What is Viracta Therapeutics’s stock symbol?

    The ticker symbol for Viracta Therapeutics is VIRX.

  • What is the current stock price of Viracta Therapeutics?

    As of 14-Jul-2025 the stock price of Viracta Therapeutics is $0.01.

  • What is the current market cap of Viracta Therapeutics?

    The current market capitalization of Viracta Therapeutics is $401K.

  • Who are Viracta Therapeutics’s competitors?

    Blueprint Medicines, Cytodyn, NexImmune, Kite Pharma, and Peloton Therapeutics are some of the 56 competitors of Viracta Therapeutics.

  • What is Viracta Therapeutics’s annual earnings per share (EPS)?

    Viracta Therapeutics’s EPS for 12 months was -$1.10.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »